Regulatory standards must be stronger for quality medicines: Health secy

During the meeting, Srivastava urged state drug regulators to ensure that medicines are sold only through prescriptions so that narcotic drugs are not diverted for trafficking or other illicit uses

pharma, pharma firm, medicines
Photo: Pexels
Press Trust of India New Delhi
1 min read Last Updated : Feb 25 2025 | 11:28 AM IST

State drug regulators should ensure that medicines are sold only through prescriptions so that narcotic drugs are not diverted for trafficking or other illicit uses, Union Health Secretary Punya Salila Srivastav has said.

Chairing a meeting with state drug regulators to address illicit use of psychotropic drugs under the Nasha Mukt Bharat Abhiyan and strengthen regulatory capacities of states and UTs on Monday, she said regulatory standards need to be strong to ensure that only quality and effective medicines circulate in the country.

During the meeting, Srivastava urged state drug regulators to ensure that medicines are sold only through prescriptions so that narcotic drugs are not diverted for trafficking or other illicit uses.

She also complimented Central Drugs Standard Control Organisation (CDSCO) and state drug regulators for completing risk-based inspections of 905 drug manufacturing and testing firms, resulting in 694 actions being taken so far.

The meeting comes in the wake of the Drugs Controller General of India (DCGI) prohibiting the production and export of all combinations of pain relief medicines tapentadol and carisoprodol, following reports that unapproved combinations of these drugs were exported to West African countries by a Mumbai-based pharma firm causing an opioid crisis there.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Health sectorHealth MinistryMedicines in India

First Published: Feb 25 2025 | 11:27 AM IST

Next Story